These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 23844550

  • 1. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.
    Kucukevcilioglu M, Bayer A, Uysal Y, Altinsoy HI.
    Clin Exp Ophthalmol; 2014 Mar; 42(2):126-31. PubMed ID: 23844550
    [Abstract] [Full Text] [Related]

  • 2. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.
    Park J, Cho HK, Moon JI.
    Jpn J Ophthalmol; 2011 Jan; 55(1):22-7. PubMed ID: 21331688
    [Abstract] [Full Text] [Related]

  • 3. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs.
    Inoue K, Shiokawa M, Wakakura M, Tomita G.
    J Glaucoma; 2013 Jan; 22(8):626-31. PubMed ID: 22936280
    [Abstract] [Full Text] [Related]

  • 4. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT, Trattler WB, Matossian C, Williams J, Hollander DA.
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [Abstract] [Full Text] [Related]

  • 5. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost.
    Nakakura S, Tabuchi H, Kiuchi Y.
    Optom Vis Sci; 2011 Sep; 88(9):1140-4. PubMed ID: 21666524
    [Abstract] [Full Text] [Related]

  • 6. Periocular changes in topical bimatoprost and latanoprost use.
    Karslioğlu MZ, Hoşal MB, Tekeli O.
    Turk J Med Sci; 2015 Sep; 45(4):925-30. PubMed ID: 26422869
    [Abstract] [Full Text] [Related]

  • 7. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness.
    Zhong Y, Shen X, Yu J, Tan H, Cheng Y.
    Cornea; 2011 Aug; 30(8):861-4. PubMed ID: 21499083
    [Abstract] [Full Text] [Related]

  • 8. Latanoprost-induced prostaglandin-associated periorbitopathy.
    Tan J, Berke S.
    Optom Vis Sci; 2013 Sep; 90(9):e245-7; discussion 1029. PubMed ID: 23912967
    [Abstract] [Full Text] [Related]

  • 9. Factors Related to Prostaglandin-Associated Periorbitopathy in Glaucoma Patients.
    Patradul C, Tantisevi V, Manassakorn A.
    Asia Pac J Ophthalmol (Phila); 2017 Sep; 6(3):238-242. PubMed ID: 28379653
    [Abstract] [Full Text] [Related]

  • 10. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.
    Eisenberg DL, Toris CB, Camras CB.
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S105-15. PubMed ID: 12204706
    [Abstract] [Full Text] [Related]

  • 11. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
    Schwartz GF, Tan J, Kotak S.
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
    [Abstract] [Full Text] [Related]

  • 12. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
    Reardon G, Schwartz GF, Mozaffari E.
    Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
    [Abstract] [Full Text] [Related]

  • 13. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials.
    Honrubia F, García-Sánchez J, Polo V, de la Casa JM, Soto J.
    Br J Ophthalmol; 2009 Mar; 93(3):316-21. PubMed ID: 19019922
    [Abstract] [Full Text] [Related]

  • 14. Adverse periocular reactions to five types of prostaglandin analogs.
    Inoue K, Shiokawa M, Higa R, Sugahara M, Soga T, Wakakura M, Tomita G.
    Eye (Lond); 2012 Nov; 26(11):1465-72. PubMed ID: 23037910
    [Abstract] [Full Text] [Related]

  • 15. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial.
    Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP.
    Arch Ophthalmol; 2005 Feb; 123(2):186-92. PubMed ID: 15710814
    [Abstract] [Full Text] [Related]

  • 16. Periorbital changes associated with prostaglandin analogs in Korean patients.
    Kim HW, Choi YJ, Lee KW, Lee MJ.
    BMC Ophthalmol; 2017 Jul 17; 17(1):126. PubMed ID: 28716077
    [Abstract] [Full Text] [Related]

  • 17. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy.
    Sharpe ED, Reynolds AC, Skuta GL, Jenkins JN, Stewart WC.
    Curr Eye Res; 2007 Dec 17; 32(12):1037-43. PubMed ID: 18085467
    [Abstract] [Full Text] [Related]

  • 18. Unilateral Prostaglandin-Associated Periorbitopathy: A Syndrome Involving Upper Eyelid Retraction Distinguishable From the Aging Sunken Eyelid.
    Rabinowitz MP, Katz LJ, Moster MR, Myers JS, Pro MJ, Spaeth GL, Sharma P, Stefanyszyn MA.
    Ophthalmic Plast Reconstr Surg; 2015 Dec 17; 31(5):373-8. PubMed ID: 25393907
    [Abstract] [Full Text] [Related]

  • 19. Proposal of a simple grading system integrating cosmetic and tonometric aspects of prostaglandin-associated periorbitopathy.
    Tanito M, Ishida A, Ichioka S, Takayanagi Y, Tsutsui A, Manabe K, Shirakami T, Sugihara K, Matsuo M.
    Medicine (Baltimore); 2021 Aug 27; 100(34):e26874. PubMed ID: 34449456
    [Abstract] [Full Text] [Related]

  • 20. Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma.
    Faridi UA, Saleh TA, Ewings P, Venkateswaran M, Cadman DH, Samarasinghe RA, Vodden J, Claridge KG.
    Clin Exp Ophthalmol; 2010 Oct 27; 38(7):678-82. PubMed ID: 20456437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.